| Schedule of Segment Reporting Information, by Segment |
The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | | (In thousands) | 2025 | | 2024 | | 2025 | | 2024 | | | | Product revenue, net | $ | 12,455 | | | $ | 8,615 | | | $ | 21,181 | | | $ | 16,804 | | | | | PK activator (PYRUKYND®) direct expenses - research and development | (29,809) | | | (27,968) | | | (51,130) | | | (54,004) | | | | | Compensation and related expenses - research and development | (27,594) | | | (27,476) | | | (60,584) | | | (55,110) | | | | | Total selling, general and administrative expenses | (45,869) | | | (35,536) | | | (87,396) | | | (66,550) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Other segment items* | (21,203) | | | (13,753) | | | (23,380) | | | (18,807) | | | | | Net loss | $ | (112,020) | | | $ | (96,118) | | | $ | (201,309) | | | $ | (177,667) | | | |
*Other segment items primarily include cost of sales, other research and development expenses and interest income.
|